From left: Nobel laureate Robert Lefkowitz and Septerna CEO Jeff Finer

A new Third Rock start­up seeks a 'sec­ond gold­en age' of GPCR drug dis­cov­ery based on No­bel lau­re­ate's work

Among the most pro­lif­ic tar­get class­es in all of drug dis­cov­ery, a group of mem­brane pro­teins known as G pro­tein-cou­pled re­cep­tors (GPCR) have been the fo­cus of hun­dreds of ap­proved med­i­cines over sev­er­al decades. But a team out of Third Rock Ven­tures thinks there’s a lot more to learn about GPCRs, and it’s work­ing with the god­fa­ther of the field to find a break­through.

With back­ing from Third Rock and a clutch of A-list biotech VCs on board, Septer­na Ther­a­peu­tics launched Thurs­day with $100 mil­lion in fund­ing and an al­ready bustling pipeline and new tech­nol­o­gy of­fer­ing re­searchers their best-ever look at the func­tion and shape of GPCRs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.